What is Artios Pharma?
Artios Pharma is a pioneer in the field of DNA damage response, focusing on the development of next-generation anti-cancer therapies. The company's research and development efforts are centered on precision medicine, specifically targeting the survival pathways that allow cancer cells to persist. Its clinical-stage portfolio includes the ATR inhibitor alnodesertib and the DNA Polymerase theta inhibitor ART6043. Furthermore, the company is actively expanding its reach into pre-clinical programs, including DDRi-ADCs, which leverage differentiated pharmaceutical properties to enhance patient outcomes. By integrating deep scientific expertise with innovative biological approaches, Artios Pharma is positioned at the forefront of the oncology drug development landscape.
How much funding has Artios Pharma raised?
Artios Pharma has raised a total of $385.2M across 4 funding rounds:
Series A
$33.2M
Series B
$84M
Series C
$153M
Series D
$115M
Series A (2016): $33.2M with participation from AbbVie Ventures, SV Life Sciences, Arix Bioscience, Merck Ventures, and Imperial Innovations Group plc
Series B (2018): $84M, investors not publicly disclosed
Series C (2021): $153M supported by Piper Sandler, TCG X, Omega Funds, Sofinnova Partners, Avidity Partners, Invus, and Deep Track Capital
Series D (2025): $115M, investors not publicly disclosed
Key Investors in Artios Pharma
AbbVie Ventures
AbbVie is a research-driven biopharmaceutical company that invests in innovative technologies to address significant unmet medical needs.
SV Life Sciences
A specialist investment firm backing innovative health care and life science companies, providing capital and sector expertise from early growth through scale.
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
What's next for Artios Pharma?
With the successful closure of its latest financing round, Artios Pharma is well-positioned to accelerate the clinical development of its lead candidates. The strategic allocation of this capital will likely focus on advancing alnodesertib and ART6043 through critical trial milestones, while simultaneously scaling its pre-clinical DDRi-ADC programs. As the company moves deeper into its lifecycle, the focus will shift toward potential regulatory pathways and the expansion of its intellectual property portfolio. The continued support from specialized life science investors provides the operational runway required to transition from a research-heavy entity to a mature clinical-stage organization capable of delivering transformative treatments to the oncology market.
See full Artios Pharma company page
